Clinical Trials for Advanced Solid Tumors: Chemotherapy, Targeted Therapy, and Immunotherapy
This community focuses on the clinical evaluation of treatment regimens for advanced solid tumors, specifically testing the efficacy and safety of chemotherapy, targeted agents, and immune checkpoint inhibitors in patients with lung, ovarian, head and neck, and bladder cancers.
The research is dominated by phase III trials and case reports evaluating platinum-based chemotherapy, often combined with targeted therapies or immunotherapy. Recurring applications include non-small cell lung cancer, ovarian cancer, squamous cell carcinoma of the head and neck, and urothelial carcinoma. The work centers on locally advanced and metastatic disease states, with a strong emphasis on neoadjuvant settings and the assessment of response rates and survival outcomes in patient populations.
The largest share of the community's output is found in platinum research, accounting for 9.4% of all platinum research and comprising 12,566 papers here. Radium research also shows a notable share at 1.2%, while bromine and iridium each contribute 0.5%.
The community comprises 37,047 papers, published primarily in the Journal of Clinical Oncology, Frontiers in Oncology, and Cancers.
Recent work continues to focus on combination therapies for advanced solid tumors, including studies on perioperative immunotherapy for bladder and lung cancer, and targeted treatments for EGFR-mutated non-small cell lung cancer and platinum-resistant ovarian cancer.